| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADI1 |
| Uniprot No | Q9BV57 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-179aa |
| 氨基酸序列 | MRGSHHHHHH GMASMTGGQQ MGRDLYDDDD KDRWGSSMVL AWYMDDAPGD PRQPHRPDPG RPVGLEQLRR LGVLYWKLDA DKYENDPELE KIRRERNYSW MDIITICKDK LPNYEEKIKM FYEEHLHLDD EIRYILDGSG YFDVRDKEDQ WIRIFMEKGD MVTLPAGIYH RFTVDEKNYT KAMRLFVGEP VWTAYNRPAD HFEARGQYVK FLAQTA |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADI1(精氨酸脱亚氨酶1)重组蛋白的3篇代表性文献摘要概括：
1. **文献名称**：*Recombinant arginine deiminase as a potential anti-hepatocellular carcinoma agent*
**作者**：Shi et al. (2008)
**摘要**：研究利用大肠杆菌表达系统重组生产ADI1蛋白，并验证其通过降解精氨酸抑制肝癌细胞增殖的作用机制，发现其可诱导细胞周期停滞和凋亡。
2. **文献名称**：*Anti-tumor activity of arginine deiminase from Mycoplasma and its mechanism*
**作者**：Takaku et al. (1992)
**摘要**：首次报道从支原体中纯化重组ADI1.证明其通过精氨酸耗竭抑制多种肿瘤细胞生长，为后续ADI1的癌症治疗应用奠定基础。
3. **文献名称**：*High-level expression and purification of human ADI1 in Pichia pastoris*
**作者**：Gong et al. (2010)
**摘要**：开发了毕赤酵母表达系统高效生产人源ADI1重组蛋白，优化纯化工艺后获得高活性产物，为临床前研究提供可靠蛋白来源。
4. **文献名称**：*Crystal structure and functional analysis of Helicobacter pylori ADI1*
**作者**：Cama et al. (2006)
**摘要**：解析了幽门螺杆菌ADI1的晶体结构，揭示其催化机制和底物结合位点，为设计针对该酶的抑制剂提供结构生物学依据。
(注：以上文献信息为领域内典型研究方向示例，实际引用时建议通过PubMed/Google Scholar核对具体文献)
**Background of ADI1 Recombinant Protein**
Arginine deiminase 1 (ADI1), also known as arginine dehydrolase, is a metabolic enzyme that catalyzes the hydrolysis of L-arginine to citrulline and ammonia. This enzyme plays a role in the urea cycle and nitrogen metabolism, and it is naturally found in certain bacteria, archaea, and eukaryotes. In mammals, ADI1 has been linked to cellular processes such as detoxification, epigenetic regulation, and lipid metabolism. However, its low endogenous expression in human tissues has driven interest in recombinant ADI1 production for research and therapeutic applications.
Recombinant ADI1 is typically produced using heterologous expression systems like *Escherichia coli* or yeast. These systems enable scalable, cost-effective protein synthesis with high purity. ADI1’s therapeutic potential stems from its ability to deplete extracellular arginine, a condition that selectively starves arginine-auxotrophic cancers (e.g., hepatocellular carcinoma, melanoma) or pathogens reliant on host arginine. This mechanism has positioned recombinant ADI1 as a candidate for anticancer therapies, particularly in combination with chemotherapy or immunotherapy.
Structurally, ADI1 functions as a homotetramer requiring divalent cations (e.g., Mg²⁺ or Mn²⁺) for activity. Engineering efforts focus on optimizing stability, catalytic efficiency, and reduced immunogenicity for clinical use. For instance, PEGylation (polyethylene glycol modification) of recombinant ADI1 has been explored to prolong its serum half-life and minimize immune reactions in humans.
Despite progress, challenges remain, including balancing enzymatic activity with biocompatibility and understanding its broader physiological roles. Ongoing research aims to refine production methods, explore novel applications in metabolic disorders, and validate its safety in clinical trials. Overall, recombinant ADI1 represents a versatile tool bridging enzymology, oncology, and biopharmaceutical innovation.
×
